PHARMING GROUP NV - ADR (PHAR) Stock Fundamental Analysis
NASDAQ:PHAR - US71716E1055 - ADR
15.26 USD
+0.39 (+2.62%)
PHAR gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. Both the profitability and the financial health of PHAR get a neutral evaluation. Nothing too spectacular is happening here. PHAR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
PHAR had negative earnings in the past year.
PHAR had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PHAR reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: PHAR reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.84%, PHAR belongs to the top of the industry, outperforming 88.19% of the companies in the same industry.
With an excellent Return On Equity value of -3.42%, PHAR belongs to the best of the industry, outperforming 90.22% of the companies in the same industry.
PHAR's Return On Invested Capital of 5.41% is amongst the best of the industry. PHAR outperforms 92.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.84% | ||
| ROE | -3.42% | ||
| ROIC | 5.41% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Operating Margin value of 7.21%, PHAR belongs to the best of the industry, outperforming 91.14% of the companies in the same industry.
PHAR has a better Gross Margin (89.31%) than 91.14% of its industry peers.
In the last couple of years the Gross Margin of PHAR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.21% | ||
| PM (TTM) | N/A | ||
| GM | 89.31% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHAR is destroying value.
PHAR has more shares outstanding than it did 1 year ago.
PHAR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PHAR has an improved debt to assets ratio.
2.2 Solvency
PHAR has an Altman-Z score of 3.51. This indicates that PHAR is financially healthy and has little risk of bankruptcy at the moment.
PHAR's Altman-Z score of 3.51 is fine compared to the rest of the industry. PHAR outperforms 74.17% of its industry peers.
The Debt to FCF ratio of PHAR is 4.26, which is a neutral value as it means it would take PHAR, 4.26 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.26, PHAR belongs to the top of the industry, outperforming 93.17% of the companies in the same industry.
PHAR has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.50, PHAR is doing worse than 73.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.26 | ||
| Altman-Z | 3.51 |
ROIC/WACC0.79
WACC6.88%
2.3 Liquidity
PHAR has a Current Ratio of 2.79. This indicates that PHAR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PHAR (2.79) is worse than 66.61% of its industry peers.
A Quick Ratio of 2.07 indicates that PHAR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.07, PHAR is doing worse than 72.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 50.00% over the past year.
PHAR shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.44%.
Measured over the past years, PHAR shows a quite strong growth in Revenue. The Revenue has been growing by 10.64% on average per year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%175%
Revenue 1Y (TTM)22.44%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%25.79%
3.2 Future
The Earnings Per Share is expected to grow by 54.68% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 9.43% on average over the next years. This is quite good.
EPS Next Y102.62%
EPS Next 2Y42.33%
EPS Next 3Y60.27%
EPS Next 5Y54.68%
Revenue Next Year17.66%
Revenue Next 2Y12.08%
Revenue Next 3Y10.96%
Revenue Next 5Y9.43%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
PHAR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 2464.61 indicates a quite expensive valuation of PHAR.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PHAR indicates a rather cheap valuation: PHAR is cheaper than 86.35% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of PHAR to the average of the S&P500 Index (22.69), we can say PHAR is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2464.61 |
4.2 Price Multiples
92.99% of the companies in the same industry are more expensive than PHAR, based on the Enterprise Value to EBITDA ratio.
PHAR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PHAR is cheaper than 93.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.7 | ||
| EV/EBITDA | 24.53 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as PHAR's earnings are expected to grow with 60.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.33%
EPS Next 3Y60.27%
5. Dividend
5.1 Amount
PHAR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PHAR (9/5/2025, 8:00:01 PM)
15.26
+0.39 (+2.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.96%
Inst Owner Change13.98%
Ins Owners1.41%
Ins Owner ChangeN/A
Market Cap1.05B
Analysts88.57
Price Target18.59 (21.82%)
Short Float %0%
Short Ratio0.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.45%
Min EPS beat(2)-42.39%
Max EPS beat(2)123.3%
EPS beat(4)2
Avg EPS beat(4)19%
Min EPS beat(4)-42.39%
Max EPS beat(4)123.3%
EPS beat(8)3
Avg EPS beat(8)-63.09%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)11.02%
Min Revenue beat(2)8.68%
Max Revenue beat(2)13.37%
Revenue beat(4)3
Avg Revenue beat(4)6.98%
Min Revenue beat(4)-5.54%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)2.17%
Revenue beat(12)6
Avg Revenue beat(12)-0.82%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.57%
PT rev (3m)18.22%
EPS NQ rev (1m)-2.42%
EPS NQ rev (3m)-207.25%
EPS NY rev (1m)-96.77%
EPS NY rev (3m)-96.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.24%
Revenue NY rev (1m)3.32%
Revenue NY rev (3m)2.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2464.61 | ||
| P/S | 3.08 | ||
| P/FCF | 34.7 | ||
| P/OCF | 33.67 | ||
| P/B | 4.36 | ||
| P/tB | 10.09 | ||
| EV/EBITDA | 24.53 |
EPS(TTM)-0.13
EYN/A
EPS(NY)0.01
Fwd EY0.04%
FCF(TTM)0.44
FCFY2.88%
OCF(TTM)0.45
OCFY2.97%
SpS4.96
BVpS3.5
TBVpS1.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.84% | ||
| ROE | -3.42% | ||
| ROCE | 6.84% | ||
| ROIC | 5.41% | ||
| ROICexc | 8.34% | ||
| ROICexgc | 20.09% | ||
| OM | 7.21% | ||
| PM (TTM) | N/A | ||
| GM | 89.31% | ||
| FCFM | 8.87% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score6
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.26 | ||
| Debt/EBITDA | 2.95 | ||
| Cap/Depr | 5.84% | ||
| Cap/Sales | 0.27% | ||
| Interest Coverage | 3.72 | ||
| Cash Conversion | 77.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.07 | ||
| Altman-Z | 3.51 |
F-Score6
WACC6.88%
ROIC/WACC0.79
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%175%
EPS Next Y102.62%
EPS Next 2Y42.33%
EPS Next 3Y60.27%
EPS Next 5Y54.68%
Revenue 1Y (TTM)22.44%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%25.79%
Revenue Next Year17.66%
Revenue Next 2Y12.08%
Revenue Next 3Y10.96%
Revenue Next 5Y9.43%
EBIT growth 1Y248.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.21%
EBIT Next 3Y76.77%
EBIT Next 5Y88.46%
FCF growth 1Y288.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y313.32%
OCF growth 3YN/A
OCF growth 5YN/A